

**Breakfast Briefing presentation title:**  
**Are pain models predictive of efficacy: myth or reality?**

The current and major challenge in developing new medication for chronic pain is the characterization and validation of translational links from animals' models to patients and vice versa, pain diseases to pain mechanisms and lastly pain diseases and symptoms.

Designing an optimal early clinical development plan for a chronic pain compound is complex and challenging. It should test for various pain mechanisms as well trying to translate these mechanisms in very well characterized patient populations. Each characterization represents an equivalent of proof of mechanism per se, if successful.

We will attempt to review translational animal and human pain models approaches and will present examples of strategies (including their limitations) for developing new pain molecules.

Inclusion of healthy volunteers versus patients will be evaluated and commented, as well as examples of various pain models (from the simplest to the most complex ones).

**Submitted for oral presentation at the Exploratory Clinical Development World Europe, London May 2010**

**Speakers: Dr A. Pereira, Clinical Research Scientist Advisor, Aepodia.  
Prof L. Arend Nieslen, Director Research & Development, C4Pain.**